ライフサイエンスコーパス: enrolled patients

1 Enrolled patients received capecitabine (825 mg/m(2) orally t

2 itreal anti-VEGF injections, as well as injections per 1000 enrolled patients per general category of ophthalmic disease,

3 Of 152 enrolled patients, 134 (n=68 LB and 66 RF; 63% men; mean age,

4 163 (98%) of 166 enrolled patients had HCV genotype 1b infection, and three (2

5 Of 1798 enrolled patients, 1764 had data available for adjudication a

6 Out of 226 enrolled patients, 123 (54%) were female, and 198 (87%) were

7 Results Of 299 enrolled patients, 127 patients treated with duloxetine and 1

8 No patients developed inhibitors to rFIXFc; in the 30 enrolled patients the most common adverse events were nasopha

9 Among 309 enrolled patients, 286 were randomly assigned to the maintena

10 y intakes minus the REE), and survival were recorded.Of 390 enrolled patients, 49% of subjects were hypermetabolic, 30% o

11 Results Of 41 enrolled patients, 38 were evaluable for MTD determination.

12 46 of 48 enrolled patients were assessable (two patients had unconfirm

13 In all 53 enrolled patients (the safety analysis set), common treatment

14 Patients and Methods Of the 534 enrolled patients, 504 were evaluable.

15 Among 63 enrolled patients, median age was 66 years (range, 30-92).

16 89 of 200 planned patients were randomly assigned: 60 (67%) enrolled patients were assigned to the lenalidomide group and

17 All enrolled patients received at least one dose of pembrolizumab

18 All enrolled patients were assessed for the primary outcome, whic

19 All enrolled patients were included in primary analyses, with the

20 pectives on the demographic and clinical characteristics of enrolled patients, characteristics of participating centers,

21 e centrally confirmed pretreatment T790M mutation status of enrolled patients (T790M positive or negative).

22 Conclusion Outcomes for newly diagnosed, prospectively enrolled patients with non-GCB DLBCL were more favorable than

23 We prospectively enrolled patients with IA (>/=3 episodes/y) who then underwen

24 an investigational new drug authorization, we prospectively enrolled patients with newly diagnosed HL (n = 19) and NHL (n

25 PATIENTS AND The AREN0532 study enrolled patients with very low-risk Wilms tumor confirmed by

26 This observational case-control study enrolled patients from September 1, 2016, through May 31, 201

27 and Methods This randomized, double-blind, phase III study enrolled patients with histologically confirmed RR-DTC strati

28 The ongoing OCEAN study enrolled patients treated with ranibizumab for neovascular ag

29 phase III study conducted in a US cooperative group system, enrolled patients with advanced grades 1 and 2 NETs with prog

30 Studies that enrolled patients with stage III disease receiving radiothera

31 comparator groups of eight randomised clinical trials that enrolled patients with metastatic castration-resistant prosta

32 Within these enrolled patients, we selected the eyes whose fundoscopic app

33 The ACOSOG Z0011 phase 3 randomized clinical trial enrolled patients from May 1999 to December 2004 at 115 sites

34 c review of cohort studies and randomized controlled trials enrolled patients with nonvalvular AF not treated with oral a

35 Results Trials enrolled patients from 1987 to 2011.

36 inclusion if they were phase 3 randomized clinical trials, enrolled patients with atrial fibrillation or venous thromboe

37 We enrolled patients 6 months of age or older who presented with

38 We enrolled patients aged 18 years or older with HCV genotype 1,

39 We enrolled patients from across the US National Clinical Trials

40 We enrolled patients from five academic PICUs between 2008 and 2

41 We enrolled patients who had squamous or non-squamous non-small-

42 We enrolled patients with occlusion of the intracranial internal

43 We enrolled patients with primary refractory or relapsed myeloma

44 We enrolled patients with treatment-refractory metastatic SCCA,

45 domised, double-blind, placebo-controlled phase 2 study, we enrolled patients at 36 referral sites in North America, Euro

46 In this observational cohort study, we enrolled patients with idiopathic or heritable pulmonary arte

47 this two-cohort, single-arm, open-label, phase 2 study, we enrolled patients with soft-tissue sarcoma or bone sarcoma fr

48 open-label, parallel-group, randomised controlled trial, we enrolled patients aged 18 years or older with type 2 diabetes

49 , randomized, registry-based, open-label clinical trial, we enrolled patients with either ST-segment elevation myocardial

50 POLARIS-2, which enrolled patients infected with all HCV genotypes with or wit